Edition:
India

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

15.24USD
23 Oct 2020
Change (% chg)

$-0.53 (-3.36%)
Prev Close
$15.77
Open
$15.64
Day's High
$15.73
Day's Low
$14.89
Volume
26,215
Avg. Vol
36,547
52-wk High
$19.23
52-wk Low
$5.65

Latest Key Developments (Source: Significant Developments)

Kalvista Pharma Says Martin Edwards Elected As Chair
Monday, 1 Jul 2019 

July 1 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS.KALVISTA PHARMACEUTICALS INC - CHAIR RICHARD H. ALDRICH RESIGNS IN PLANNED TRANSITION.KALVISTA PHARMACEUTICALS INC - MARTIN EDWARDS ELECTED AS CHAIR.  Full Article

Kalvista Pharmaceuticals Files For Offering Of Up To $50 Mln
Saturday, 30 Mar 2019 

March 29 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $50.0 MILLION OF COMMON STOCK - SEC FILING.  Full Article

Kalvista Pharmaceuticals Inc Reports Fiscal Q3 Loss Per Share $0.23
Thursday, 14 Mar 2019 

March 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL THIRD QUARTER RESULTS.KALVISTA PHARMACEUTICALS INC QTRLY REVENUE WAS $3.9 MILLION FOR THREE MONTHS ENDED JANUARY 31, 2019, COMPARED TO $2.3 MILLION FOR SAME PERIOD IN 2018.KALVISTA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.23.KALVISTA PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $111.1 MILLION AS OF JANUARY 31, 2019.  Full Article

Kalvista Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Saturday, 15 Dec 2018 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Kalvista Pharmaceuticals Reports Fiscal Second Quarter Results
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS.KALVISTA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.22.KALVISTA PHARMACEUTICALS - KVD900 ENLARGED PHASE 2 TRIAL ON TRACK FOR POTENTIAL ON-DEMAND TREATMENT OF ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA.KALVISTA PHARMACEUTICALS INC - INTRAVITREAL DIABETIC MACULAR EDEMA CANDIDATE KVD001 PHASE 2 TRIAL ENROLLMENT ON TRACK.KALVISTA PHARMACEUTICALS INC - OPERATIONS FUNDED INTO 2021.KALVISTA PHARMACEUTICALS INC - QTRLY REVENUE $5.6 MILLION VERSUS $1.1 MILLION.  Full Article

Kalvista Pharmaceuticals Provides Clinical Update On Kvd900
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS PROVIDES CLINICAL UPDATE ON KVD900.KALVISTA PHARMACEUTICALS - ENLARGED PHASE 2 STUDY TO BEGIN IN 2018 FOR POTENTIAL ACUTE TREATMENT OF HEREDITARY ANGIOEDEMA; DATA EXPECTED IN LATE 2019.KALVISTA PHARMACEUTICALS INC - FOOD EFFECT STUDY INDICATES NO DOSING LIMITATIONS FROM FOOD AND CONFIRMS RAPID UPTAKE AND HIGH EXPOSURE.  Full Article